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CAUSATION IN HEPATITIS B VACCINATION LITIGATION IN FRANCE:
BREAKING THROUGH SCIENTIFIC UNCERTAINTY?
JEAN-SÉBASTIEN BORGHETTI1
Since the 1990s, significant litigation has developed in France in con-
nection with hepatitis B vaccines. Plaintiffs claim compensation for dam-
age resulting from demyelinating diseases, such as multiple sclerosis, al-
legedly caused or exacerbated by these vaccines. These cases are 
particularly complex, due to the state of continuing scientific uncertainty as 
to the possible link between the hepatitis B vaccination and the appearance 
or development of demyelinating diseases.
Problems raised by scientific uncertainty are rather new to lawyers, at 
least in France and in the context of tort law. Traditional rules, especially 
those contained in the Civil code (Code civil), the Magna Carta of French 
law drafted in 1804, have not been devised to deal with such problems, and 
judges, like legal academics, are ill at ease. They lack the conceptual tools 
that could help them apprehend and categorize the complex issues at stake 
in these situations of scientific uncertainty. Yet, French courts, true to their 
traditional plaintiff-friendly approach,2 have done their best efforts to grant 
compensation to plaintiffs in hepatitis B vaccine cases. In order to do so, 
they have in effect broken through, or at least bypassed, scientific uncer-
tainty, using various, more or less subtle, mechanisms. The development of 
hepatitis B vaccine litigation in France, discussed in Part I of this article,
has led to a bypassing of scientific uncertainty. Part II examines why the 
current state of French law on this issue is not convincing and what the
paths are for improvement.
I. THE DEVELOPMENT OF HEPATITIS B VACCINE LITIGATION IN 
FRANCE
The solutions reached by French courts in hepatitis B vaccine cases 
are better understood against the context in which this litigation developed.
1. Professor of Private Law, Université Panthéon-Assas (Paris II), France.
2. See S. Whittaker, La responsabilité pour fait personnel dans l’Avant-projet de réforme du 
droit de la responsabilité: donner voix aux silences du Code civil, in REVUE DES CONTRATS 89, 99 
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A. The Context of Hepatitis B Vaccine Litigation
Section 1 discusses how hepatitis B vaccine cases first appeared in a 
specific medical and scientific context. Section 2 examines how such cases 
have been dealt with in France’s specific legal context.
1. The Medical and Scientific Context
Hepatitis B is an extremely common viral pathology affecting the liv-
er. According to some estimations, between 3% and 6% of the world’s 
population are currently carrying the hepatitis B virus, and about one in 
three human beings have been infected by the virus at some point in their 
lives.3 Most adults affected by hepatitis B get rid of the virus spontaneous-
ly. However, around 10% become chronic carriers.4 This represents an es-
timated 240 million people worldwide.5 Chronic carriers are exposed to a 
high risk of cirrhosis and liver cancer. Some medical treatments against 
chronic hepatitis B provide good results, but no drug is currently able to 
eradicate the disease. Moreover, chronic carriers are more likely to pass the 
virus on to other persons. Transmission of the virus results from exposure 
to infectious blood or body fluids containing blood. Possible forms of 
transmission include sexual contact, blood transfusions, reuse of contami-
nated needles and syringes, as well as vertical in utero transmission from 
mother to child. According to the World Health Organization (WHO), ap-
proximately 780,000 people die globally of hepatitis B each year.6 There-
fore, fighting this disease is a serious public health issue.
The vaccination against hepatitis B has been available since 1982 and 
is advocated by the WHO as an efficient means to prevent the disease and 
fight against its extension. It was made compulsory in France for health 
care professionals (professionnels de santé) in 1991.7 Three years later, in 
3. Hepatitis B, WORLD HEALTH ORG. (WHO),




7. Loi 91-73 du 18 janvier 1991 portant dispositions relatives à la santé publique et aux assur-
ances sociales [Law 91-73 of January 18, 1991 on the Provisions Relating to Public Health and Social 
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July 1994, the French Ministry of Health launched a mass immunization 
campaign against hepatitis B, especially targeting teenagers. The vaccina-
tion was not made compulsory, however. In the following years, cases were 
reported in which persons manifested symptoms of demyelinating diseases, 
such as multiple sclerosis or Guillain-Barré syndrome, after they had re-
ceived the vaccine. The idea then spread that the hepatitis B vaccination 
could cause such diseases. This led the Minister of Health in 1998 to call a 
suspension of the vaccination campaign launched a few years before. The 
campaign never resumed. In the meantime, the debate on the advisability
and possible side effects of the hepatitis B vaccination has been ongoing,
even though the WHO,8 the French Medical Academy,9 and the French 
High Council for Public Health10 continue to recommend the vaccination.
Demyelination is the loss of the myelin sheath, which insulates the 
nerves. It is the source of neurodegenerative autoimmune diseases, includ-
ing multiple sclerosis and Guillain-Barré syndrome. The etiology of these
demyelinating diseases is still a matter of debate. It is believed that such 
diseases result from some combination of genetic, environmental, and in-
fectious factors, but no definitive explanation has been found.11 Yet, sever-
al epidemiological studies investigating the relationship between hepatitis 
B vaccinations and demyelinating diseases have been carried out since the 
end of the 1990s.
Until 2004, none of the published studies had found a significant sta-
tistical association between hepatitis B vaccinations and the occurrence of a 
demyelinating disease.12 During that year, however, the Hernán et al. study,
Jan. 20, 1991, p. 1048 (now CODE DE LA SANTÉ PUBLIQUE [C. PUB. H.] [CODE OF PUBLIC HEALTH] art. 
L3111-4.
8. See WORLD HEALTH ORG., TABLE 1: SUMMARY OF WHO POSITION PAPERS –
RECOMMENDATIONS FOR ROUTINE IMMUNIZATION,
http://www.who.int/immunization/policy/Immunization_routine_table1.pdf?ua=1 (last updated Feb. 27, 
2015).
9. NAT’L ACAD. OF MED., VACCINATION AGAINST HEPATITIS B IN FRANCE: MAINTENANCE 
RECOMMENDATIONS AND STRENGTHENING OF IMMUNIZATION COVERAGE 1495–96 (2008).
10. Calendrier vaccinal 2008 – Avis du Haut conseil de la sante publique, BULL.
ÉPIDÉMIOLOGIQUE HEBDOMADAIRE § 2.5 (Apr. 22, 2008),
http://www.invs.sante.fr/beh/2008/16_17/beh_16_17_2008.pdf.
11. See Bernard Zalc, Multiple Sclerosis (MS), INST. NAT’L DE LA SANTE ET DE LA RECHERCHE 
MÉDICALE,
http://www.inserm.fr/thematiques/neurosciences-sciences-cognitives-neurologie-psychiatrie/dossiers-d-
information/sclerose-en-plaques-sep (last visited Nov. 19, 2015).
12. See Alberto Ascherio et al., Hepatitis B Vaccination and the Risk of Multiple Sclerosis, 344 
NEW ENG. J. MED. 327, 327–32 (2001); Christian Confavreux et al., Vaccinations and the Risk of Re-
lapse in Multiple Sclerosis, 344 NEW ENG. J. MED. 319, 319–26 (2001); F. De Stefano et al., Vaccina-
tions and Hepatitis B Vaccine Central Nervous System Demyelinating Disease in Adults, 60 
NEUROLOGY 504–09 (2003); A. Dessa Sadovnick & David. W. Scheifele, School-Based Hepatitis B 
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titled Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis,
was published, which concluded that there was a significant association be-
tween the vaccination of adults and the occurrence of demyelinating dis-
eases within three years.13 The Global Advisory Committee on Vaccine 
Safety (“GACVS”) of the WHO quickly took a stand against this study, 
criticizing its methodology, and stating, “the evidence and argument sub-
mitted by Hernán et al. are insufficient to support the hypothesis of a link 
between the hepatitis B vaccination and multiple sclerosis.”14 Since that 
date, there has been no new study supporting the hypothesis of a link be-
tween hepatitis B vaccinations and demyelinating diseases. In fact, studies 
conducted on children and teenagers have concluded to the contrary.15
Therefore, in the current state of things, there is only one (criticized) epi-
demiological study supporting the hypothesis of a link between hepatitis B 
vaccinations and demyelinating diseases,16 whereas the other studies avail-
able apparently point to the absence of such a link, but do not allow a de-
finitive conclusion that no such link exists. Thus, the issue is still open for 
epidemiologists and scientists.
kenboom et al., Vaccinations, Demyelination and Multiple Sclerosis Study (VDAMS): A Population-
based Study in the UK, 8 PHARMACOEPIDEMIOLOGY & DRUG SAFETY S170–71 (1999); E. Touze et al., 
Hepatitis B Vaccination and First Central Nervous System Demyelinating Event: A Case-control Study,
21 NEUROEPIDEMIOLOGY 180, 180–86 (2002); Frauke Zipp et al., No Increase in Demyelinating Dis-
eases After Hepatitis B Vaccination, 5 NATURE MED. 964, 964–65 (1999).
13. M. A. Hernán et al., Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis: A 
Prospective Study, 63 NEUROLOGY 838, 838–41 (2004).
14. Global Vaccine Safety, WORLD HEALTH ORG.,
http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/index.html (last visit-
ed Nov. 28, 2015).
15. Yann Mikaeloff et al., Hepatitis B Vaccine and Risk of Relapse After a First Childhood Epi-
sode of CNS Inflammatory Demyelination, 130 BRAIN 1105, 1105–10 (2007); Yann Mikaeloff et al.,
Hepatitis B Vaccination and the Risk of Childhood-Onset Multiple Sclerosis, 161 ARCH. PEDIATR.
ADOLESC. MED. 1176, 1176–81 (2007).
16. Another study concluded that there is no link between the hepatitis B vaccination and acute 
demyelinating episodes, but a statistically significant connection was nevertheless observed for one of 
the samples under scrutiny. Yann Mikaeloff et al., Hepatitis B Vaccine and the Risk of CNS Inflamma-
tory Demyelination in Childhood, 72 NEUROLOGY 873, 873–79 (2009). However, this has been consid-
ered a fortuitous result by the authors of the study, and by the French Commission nationale de la 
pharmacovigilance and the National Academy of Medicine. See BULL. ÉPIDÉMIOLOGIQUE 
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2. The Legal Context
In order to better understand the solutions given by French courts in 
hepatitis B vaccine cases, Part (a) describes French court institutions, while 
Part (b) discusses the basic rules on proof and evidence in such cases.17
a. The French Court System
In France, there is a sharp divide between private law and public law. 
Substantive law, including rules on liability, normally varies according to 
whether the defendant is a private or a public person. Moreover, civil 
courts, which have jurisdiction in private law matters, are distinct from ad-
ministrative courts, which deal with questions pertaining to public law.
The civil court system is a three-degree one, with courts of first in-
stance,18 appellate courts (cours d’appel), and a unique Cour de cassation
at the top. The Cour de cassation is not an appeal court.19 It does not ap-
praise facts or consider evidence. Its task is to check that rules of law have 
been correctly applied. It therefore only deals with ‘questions of law,’ as 
opposed to ‘questions of fact,’—the latter being dealt with exclusively by 
first- and second-instance courts. The Cour de cassation is thus called ‘juge 
du droit,’ as opposed to lower courts, which are called ‘juges du fond’ (i.e., 
judges ruling on the merits of the case). Rulings by appellate courts con-
taining errors of law20 are quashed, and the case is then submitted to anoth-
er appellate court in order to be decided anew. If the appellate court’s deci-
sion is found to contain no error of law, it is confirmed and cannot be 
further contested. The Cour de cassation is unique, but has several cham-
bers. Although the chambers normally deal with different types of litiga-
tion, it may happen that two or more chambers will address the same legal 
issue. This can be a source of discrepancies. If a discrepancy persists on a 
given issue, and if a new case arises in connection with it, a plenary assem-
bly (assemblée plénière) may be called, in which members of all chambers 
17. For an excellent presentation of French law in English, see generally JOHN. BELL ET AL.,
PRINCIPLES OF FRENCH LAW (2d ed. 2008).
18. The name of the courts of first instance may vary depending on the field of private law in 
which they have jurisdiction.
19. See J. Bell & S. Whittaker, The Spirit of French Law, and J. Bell, Court Institutions, in BELL 
ET AL., supra note 17, at 1–2, 37.
20. The Cour de cassation only considers those aspects of the appellate court’s ruling, which are 
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sit. The assemblée plénière will take a common position on the disputed 
issue, which the various chambers will normally follow, even though they 
are not legally bound to do so (as there is no such thing as binding prece-
dent in French law).
No leave to appeal is required in order to bring a case before the Cour 
de cassation. Any appellate court ruling may be submitted to the Cour de 
cassation. This explains why the latter issues approximately 9,000 deci-
sions each year (not counting criminal cases).21 These decisions are usually 
very terse (not more than a page). The court sticks to a formal reasoning
and does not give the reasons underlying its choices. It will say if a provi-
sion has been correctly interpreted by the lower court or not, but it will not 
explain the reasons why this interpretation is correct or incorrect. Some ex-
planations can sometimes be found in the reports of the magistrates who 
have prepared the court’s decision, but these reports are only occasionally 
made public and have no authority per se. Because they are so terse, deci-
sions by the Cour de cassation usually leave great room for interpreta-
tion—if not divination.22
The administrative court system is to a large extent analogous to the 
civil courts. Courts of first instance (tribunaux administratifs) and appellate 
courts (cours administratives d’appel) are topped by the Conseil d’État.
Although the attributions of the latter may vary depending on the type of 
litigation, its role is normally the same as the Cour de cassation’s. It does 
not appraise facts or evidence and only quashes appellate courts’ rulings for 
errors of law. The Conseil d’État’s decisions are also quite terse, but the 
preparatory reports are often more easily available than with the Cour de 
cassation.23
b. Rules of Evidence
Evidence rules in French law are not as developed as they are in other 
legal systems—especially common law systems. Facts may normally be 
21. FRENCH MINISTRY OF JUSTICE, ANNUAIRE STATISTIQUE DE LA JUSTICE, ÉDITION 2011-2012,
27 (2012), http://www.justice.gouv.fr/art_pix/stat_annuaire_2011-2012.pdf.
22. All decisions by the Cour de cassation can be found on the judicial case law page of the offi-
cial French law website Légifrance by simply indicating the decision’s number. LÉGIFRANCE,
http://www.legifrance.gouv.fr/ initRechJuriJudi.do (last visited Feb. 20, 2016). 
23. All decisions by the Conseil d’État can be found on the administrative case law page of the 
official French law website Légifrance by simply indicating the decision’s number. LÉGIFRANCE,
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proven by any means.24 Additionally, there is no official standard of proof. 
Facts do not have to be established ‘on the balance of probabilities,’ or ‘be-
yond a reasonable doubt’. First- and second-instance judges freely decide if 
evidence is enough to consider a fact as established. Their appreciation is a 
matter of ‘intime conviction’ (firm personal conviction) and may not be 
challenged before the Cour de cassation or the Conseil d’État.25
When a fact cannot be directly established, its existence may be de-
duced from another fact or from a set of facts. This mechanism is called a 
presumption. Article 1353 of the Code civil provides that presumptions are 
normally “left to the learning and wisdom of the judges, who shall only 
admit serious, precise, and consistent presumptions.”26
The parties may of course bring evidence to the court, which will then 
freely appraise the value of it. However, there are no expert witnesses in 
French procedure.27 French courts do not hear evidence on technical mat-
ters. When a court needs clarification on a technical point, it will usually 
commission an expert. The expert must be independent from the parties 
and is normally required to draft a report for the court. In theory, the expert 
must report on purely factual matters and may not make any assessments of 
legal nature. This last rule, however, is difficult to apply. The court is not 
bound to follow the expert’s conclusions. Though in practice, it is only 
very seldom that a court will reject them.
B. The Solutions Reached by the Courts
It is in this general context, and also in an atmosphere of growing mis-
trust vis-à-vis vaccinations in general, that the claims regarding hepatitis B
vaccines and their possible link with the occurrence of demyelinating dis-
24. There are some exceptions, especially in regards to contracts, but they are not relevant in the 
context of hepatitis B vaccine litigation.
25. See S. Whittaker, Legal Procedure, in BELL ET AL., supra note 17, at 85–87. 
26. CODE CIVIL [C. CIV.] [CIVIL CODE] art. 1353. All citations of the French Code civil in English 
are borrowed from the English translation accessible on the French law official website Légifrance, and 
are written by David W. Grunning. LÉGIFRANCE, www.legifrance.gouv.fr (last visited Feb. 20, 2016). A
reform of French contracts law, which also encompasses rules on the proof of obligations, was adopted 
in February 2016: Ordonnance 2016-131 du 10 février 2016 portant réforme du droit des contrats, du 
régime général et de la preuve des obligations [Statute 2016-131 of February 10, 2016 Laying Down 
Reform of Contracts Law, the General Rules on Obligations and Proof of Obligations], JOURNAL
OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE [J.O.] [OFFICIAL GAZETTE OF FRANCE], Feb. 11, 2016, text 
no. 26. The reform will come into force on October 1, 2016. It maintains the substance of the rule now 
found at art. 1353, but shifts it to art. 1382 of the upcoming version of the Code civil.
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eases have been raised and adjudicated since the 1990s. These claims come 
in significant numbers and have been brought on at least four different le-
gal bases. Only two of those will be addressed here, as they are by far the 
most important in practice.28 Part 1 discusses the compulsory vaccinations 
compensation scheme, while Part 2 analyzes the product liability legisla-
tion.
1. The Compulsory Vaccinations Compensation Scheme
A 1964 statute created a special compensation scheme for injuries re-
sulting from compulsory vaccinations.29 This scheme is now regulated by 
article L. 3111–9 of the code de la santé publique (the Code of Public 
Health). A special compensation fund, ONIAM (Office national 
d’indemnisation des accidents médicaux, des affections iatrogènes et des 
infections nosocomiales), is in charge of fully compensating any damage 
directly imputable (directement imputable) to a compulsory vaccination. 
Compensation is due as soon as the plaintiff proves that damage is directly 
imputable to the compulsory vaccination. No other condition, such as neg-
ligence or the vaccine’s defectiveness, is required. Cases of compulsory 
vaccination include compulsory hepatitis B vaccinations for health care 
professionals under article L. 3111–4 of the code de la santé publique30;
but article L. 3111–9 does not apply to non-compulsory vaccinations, even 
if they were recommended, encouraged, or subsidized by the government. 
Claims based on this special compensation scheme must be brought before 
the ONIAM. The latter decides whether the conditions set by the law are 
met, and if so, offers a certain amount of damages. If a plaintiff is unsatis-
28. The two other legal bases are: CODE DE LA SÉCURITÉ [C. SOC. SEC.] [CODE OF SOCIAL
SECURITY] art. L411-1 (work accidents (accidents du travail) legislation for private sector workers), 
and Loi 86-33 du 9 janvier 1986 portant dispositions statutaires relatives à la function publique hospital-
ière [Law 86-33 of January 9, 1986 Laying Down Statutory Provisions Concerning the Public Hospital], 
JOURNAL OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE [J.O.] [OFFICIAL GAZETTE OF FRANCE], Jan. 11, 
1986, p. 535 (service accidents (accidents de service) legislation for public sector employees).
29. Loi 64-643 du 1er juillet 1964 relative à la vaccination antipoliomyélitique obligatoire et à la 
répression des infractions à certaines dispositions du code de la santé publique [Law 64-643 of July 1, 
1964 on compulsory polio immunization and suppression of violations of certain provisions of the Code 
of Public Health], JOURNAL OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE [J.O.] [OFFICIAL GAZETTE OF 
FRANCE], July 2, 1964, p. 5762.
       30. Loi 91-73 du 18 janvier 1991 portant dispositions relatives à la santé publique et aux assur-
ances sociales [Law 91-73 of January 18, 1991 on the Provisions Relating to Public Health and Social 
Insurance], JOURNAL OFFICIEL DE LA RÉPUBLIQUE FRANÇAISE [J.O.] [OFFICIAL GAZETTE OF FRANCE],
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fied with the ONIAM’s appraisal of the situation or its compensation pro-
posal, he can appeal to an administrative court.
At the end of the 1990s, litigants began filing claims with administra-
tive courts, based on article L. 3111-9, regarding damage allegedly caused 
by hepatitis B vaccinations.31 Due to the state of scientific uncertainty, 
judges initially took diverging positions on the issue of the link between 
hepatitis B vaccinations and the occurrence of demyelinating diseases.32
Things were then clarified by the Conseil d’État in four decisions handed 
down in March 2007.33 On that occasion, the court followed the opinion of 
Thierry Olson, the magistrate in charge of preparing the cases.34
In his preliminary report, Judge Olson described the (rather uncertain) 
state of the lower administrative courts’ (and of the Cour de cassation’s) 
case law on the subject at the time. He also explained the state of scientific 
uncertainty on the issue of the relationship between the hepatitis B vaccina-
tion and the occurrence of demyelinating diseases. He concluded that it was 
not possible to answer ‘yes’ or ‘no’ to the question whether the vaccination 
could cause such diseases. Yet, having said that, he went on to declare that 
vaccinations can be regarded as a factor that may trigger the appearance of 
a demyelinating disease if the subject has certain predispositions. However, 
he added, such a link between the vaccination and the occurrence of the 
disease can only be regarded as established if the first symptoms of the dis-
ease appear in the three months following the vaccination. He gave no pre-
cise scientific reason for this three-month delay.
31. “Sans préjudice des actions qui pourraient être exercées conformément au droit commun, la 
réparation d’un dommage imputable directement à une vaccination obligatoire pratiquée dans les condi-
tions mentionnées au présent chapitre, est supportée par l’État.” Until 2000, the rule now contained in 
this article was found at CODE DE LA SANTÉ PUBLIQUE [C. PUB. H.] [CODE OF PUBLIC HEALTH] art. 
L3111-9.
32. For cases negating the link, see Cour administrative d’appel [CAA] [regional administrative 
courts of appeal] Douai, June 21, 2005, 03DA01306; Cour administrative d’appel [CAA] [regional ad-
ministrative courts of appeal] Bordeaux, Dec. 6, 2005, 03BX00793; Cour administrative d’appel [CAA]
[regional administrative courts of appeal] Nantes, Oct. 13, 2005, 04NT01007; Cour administrative 
d’appel [CAA] [regional administrative courts of appeal] Douai, Oct. 17, 2006, 05DA00803; Cour ad-
ministrative d’appel [CAA] [regional administrative courts of appeal] Paris, May 15, 2006, 04PA01401. 
For cases affirming the link, see Cour administrative d’appel [CAA] [regional administrative courts of 
appeal] Paris, Nov. 5, 2002; Cour administrative d’appel [CAA] [regional administrative courts of ap-
peal] Paris, civ., May 16, 2006, 02PA03495.
33. Conseil d’État [CE] [Council of State] Mar. 9, 2007, 267635; Conseil d’État [CE] [Council of 
State] Mar. 9, 2007, 278665; Conseil d’État [CE] [Council of State] Mar. 9, 2007, 283067; Conseil 
d’État [CE] [Council of State] Mar. 9, 2007, 285288. Three of these cases were actually grounded on 
service accidents legislation and only one on compulsory vaccinations compensation rules. In all four 
cases, the Conseil addressed the issue of the link between the hepatitis B vaccination and the occurrence 
of a demyelinating disease exactly the same way.
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Unsubstantiated though it may be from a scientific point of view, 
Judge Olson’s position was endorsed by the Conseil d’État.35 The court af-
firmed two lower court decisions, which had rejected the plaintiffs’ claims.
In one case the delay between the last injection of the vaccine and the first 
symptoms of multiple sclerosis (ten months) did not support the existence 
of a causal link between the vaccination and the disease. In the second case,
the first symptoms of the disease had appeared before the vaccination and 
could therefore not be regarded as a consequence of the latter. The Conseil 
d’État quashed the two other lower court decisions, which had rejected the 
claims for lack of causation, on the ground that the short delay between the 
vaccination and the first symptoms of the disease (a couple of months in 
both cases) should have been regarded as establishing causation.
Since 2007, the Conseil d’État has stuck to this position and has con-
firmed in several decisions the rule according to which a short (bref) delay 
(three months at most) between receiving the vaccination and the occur-
rence of the first symptoms establishes causation, if no other cause for the 
disease can be identified.36 In practice, the court has thus broken through 
the veil of scientific uncertainty, establishing a new legal rule, whereby 
causation must be presumed in certain circumstances. What is striking, 
though, is that no scientific reason, nor actually any reason at all, was put 
forward by the court to justify the short delay criterion, which is a major 
condition of application of this rule.
2. Product Liability Legislation
The European Union, of which France is a member, has set up com-
mon rules on product liability for its Member States through Directive 
85/374/EEC of 25 July 1985 on the Approximation of the Laws, Regula-
tions, and Administrative Provisions of the Member States Concerning Li-
35. See supra note 32.
36. Conseil d’État [CE] [Council of State] July 25, 2007, 288052; Conseil d’État [CE] [Council 
of State] July 4, 2008, 299832; Conseil d’État [CE] [Council of State] July 11, 2008, 289763; Conseil 
d’État [CE] [Council of State] Feb. 18, 2009, 305810; Conseil d’État [CE] [Council of State] Apr. 10, 
2009, 296630; Conseil d’État [CE] [Council of State] July 24, 2009, 308876; Conseil d’État [CE] 
[Council of State] July 24, 2009, 304325; Conseil d’État [CE] [Council of State] Feb. 9, 2011, 319497; 
Conseil d’État [CE] [Council of State] Feb. 25, 2011, 324051; Conseil d’État [CE] [Council of State] 
Mar. 4, 2011, 313369; Conseil d’État [CE] [Council of State] July 28, 2011, 318466; Conseil d’État 
[CE] [Council of State] Feb. 13, 2012, 331348; Conseil d’Etat [CE] [Council of State] Feb. 17, 2012,
331277; Conseil d’État [CE] [Council of State] Nov. 8, 2012, 350886; Conseil d’État [CE] [Council of 
State] Nov. 6, 2013, 345696; Conseil d’État [CE] [Council of State] Dec. 13, 2013, 352460; Conseil 
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ability for Defective Products.37 These rules apply in France to all products 
put into circulation as of July 31, 1988.38 They make the producer liable for 
damage caused by a defect in his product.39 The producer is defined as the 
manufacturer of the product or any person who, by putting his name, 
trademark, or other distinguishing feature on the product presents himself 
as its producer.40 It is of course the injured person who must prove damage, 
the defect, and the causal relationship between defect and damage.41 The 
Directive regards a product as defective when it does not provide the safety 
a person is entitled to expect, taking all circumstances into account, includ-
ing: (a) the presentation of the product; (b) the use to which it could rea-
sonably be expected that the product would be put; and (c) the time when 
the product was put into circulation.42 The producer can escape liability if 
he proves that the state of scientific and technical knowledge at the time 
when he put the product into circulation was not such as to enable the ex-
istence of the defect to be discovered.43 Claims based on product liability 
may in theory be brought before either civil or administrative courts, de-
pending on the status (private or public) of the producer. However, there 
are only two producers marketing vaccines against hepatitis B in France, 
both of which are commercial companies, and claims against them are to be 
brought before civil courts.
The first reported product liability cases related to hepatitis B vaccina-
tions are two rulings by the Nanterre44 court of first instance on June 5,
37. Council Directive 85/374/EEC, 1985 O.J. (L 210) (EU). The rules contained in a directive 
generally need to be transposed to apply in a Member State. Transposition of Directive 85/374 was sup-
posed to take place before the end of July 1988, but France waited until May 1998 before it complied 
with its obligations. The rules set by the Directive are found in articles 1386-1 to 1386-18 of the French 
Code civil (and will be shifted to articles 1245–1245-17 when the reform of French contracts law, on 
which see supra note 26, comes into force on Oct. 1, 2016). CODE CIVIL [C. CIV.] [CIVIL CODE] arts. 
1386-1–1386-18. On the rather hectic transposition process of the Directive in France, see GENEVIÈVE 
VINEY & PATRICE JOURDAIN, LES CONDITIONS DE LA RESPONSABILITÉ ¶ 771–76 (3d ed. 1996). 
38. July 31, 1998 marked the end of the delay set for the transposition of the Directive. The cur-
rent Code civil provisions on product liability only apply to products put into circulation after May, 21 
1998. Products put into circulation before that date are subject to judge-made rules, but these have been 
modified or interpreted to match exactly those of the Directive. See Cour de cassation [Cass.] [supreme 
court for judicial matters] 1e civ., May 15, 2007, 05-17947, Bull. civ. I, No. 186.
      39. Council Directive 85/374/EEC, art. 1, 1985 O.J. (L 210) (EU).
       40. Id. art. 3. 
       41. Id. art. 4. 
       42. Id. art. 6. 
43. Id. art. 7(e). For a general analysis of the Directive, its origins, and its regime, see JANE
STAPLETON, PRODUCT LIABILITY (1994).
44. Most pharmaceutical firms in France have their headquarters in Paris and its vicinity. Hence, 
a majority of product liability cases concerning pharmaceuticals are brought before the Parisian courts 
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1998.45 The court of first instance allowed the claims and the producer ap-
pealed to the Versailles appellate court. The latter acknowledged the state 
of scientific uncertainty and stated that “the existence of a link between the 
vaccination and the occurrence of the disease cannot be scientifically prov-
en”; but it went on to say that scientific evidence did not exclude the exist-
ence of such a link.46 It then concluded that, in the cases under scrutiny, the 
time coincidence between the vaccination and the occurrence of the first 
symptoms of the disease, as well as the absence of another identified cause 
for multiple sclerosis, allowed a presumption that the vaccination had actu-
ally caused the disease.47 The appellate court thus confirmed the court of 
first instance’s rulings.48 The cases were subsequently brought before the 
Cour de cassation. In two 2003 rulings, the first civil chamber of the higher 
court quashed the appellate court’s decisions, on the ground that the lower 
judges could not regard causation between the vaccination and the disease 
as established, given the absence of scientific certainty on the possible link 
between hepatitis B vaccinations and multiple sclerosis.49
These rulings by the Cour de cassation have been interpreted as fol-
lows: the state of scientific uncertainty regarding the effects of hepatitis B 
vaccinations forbids that a causal link be established between a vaccination 
and the appearance of a demyelinating disease in a given case. This posi-
tion was followed by lower courts50 and, on at least one occasion, the first 
civil chamber of the Cour de cassation confirmed a lower court’s decision
that had rejected a claim related to a hepatitis B vaccine for lack of proven 
45. Tribunal de grande instance [TGI] [ordinary court of original jurisdiction] Nanterre, June 5, 
1998, D. 1999, 246.
       46. Cour d’appel [CA] [regional court of appeal] Versailles, civ., May 2, 2001, 98/06839, D. 
2001, 1592.
47. Id. The court also considered, on very shallow grounds, that the vaccine could be regarded as 
defective. The issue of defectiveness will be dealt with infra.
48. Cour d’appel [CA] [regional court of appeal] Versailles, civ., May 2, 2001, 98/06839, D. 
2001, 1592. For a detailed study of this decision, see Sophie Gromb & MG Kirman, Vaccination contre 
l’hépatite B et sclérose en plaques, 51 MÉDECINE ET DROIT 22 (2001); JEAN-SÉBASTIEN BORGHETTI,
LA RESPONSABILITÉ DU FAIT DES PRODUITS, ÉTUDE DE DROIT COMPARÉ ¶ 376 (2004).
49. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Sept. 23, 2003, 01-
13063 and 01-13064, Bull. civ. I, No. 188.
50. Cour d’appel [CA] [regional court of appeal] Versailles, civ., Nov. 25, 2005, 04/03953; Cour 
d’appel [CA] [regional court of appeal] Paris, civ., June 2, 2006, 03/17991; Cour d’appel [CA] [region-
al court of appeal] Lyon, civ., Nov. 22 2007, 06/02450; Cour d’appel [CA] [regional court of appeal]
Lyon, civ., Feb. 12 2008, 06/01764. Before the 2003 Cour de cassation’s rulings, the Versailles appel-
late court recognized a causal link between the hepatitis B vaccination and the occurrence of a demye-
linating disease in another case. Cour d’appel [CA] [regional court of appeal] Versailles, Sept. 12, 2003,
97/04862. However, this decision was later quashed by the Cour de cassation on the issue of the prod-
uct’s defectiveness. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Jan. 24, 2006, 
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causation between the vaccination and the occurrence of the disease.51
Plaintiffs and part of academia were very critical of this position, however.
Many described it as unfair and found it shocking that ‘victims’ could get 
no compensation.52 Critics also pointed to the position adopted by the Con-
seil d’État in 2007 to support their argument: how could the two higher 
courts take a different stance on the same important issue and create such 
inequality among plaintiffs?53
This debate apparently had an impact on the Cour de cassation. The 
court changed its position in two rulings issued on May 22, 2008. In both 
cases, the appellate courts had followed the rule established by the first civ-
il chamber in 2003 and rejected compensation claims on the ground that 
scientific uncertainty did not permit the recognition of a causal link be-
tween the hepatitis B vaccination and the occurrence of a demyelinating 
disease. Yet, the same chamber of the Cour de cassation quashed these two 
decisions. It held that the lower courts had violated the law because they 
had followed “a probabilistic approach based exclusively on the lack of
scientific and statistical link between vaccination and the development of 
the disease” (“une approche probabiliste déduite exclusivement de 
l’absence de lien scientifique et statistique entre vaccination et développe-
ment de la maladie”), whereas they should have considered whether the 
facts of the case allowed for a presumption that the vaccine caused the 
plaintiff’s disease.54 These decisions must be well understood. They have 
not affirmed that there was a causal relationship between the vaccination 
and the disease in the cases under scrutiny; but they have repudiated the 
former approach, which regarded the state of scientific uncertainty as a bar 
to product liability claims involving hepatitis B vaccines. As the Cour de 
cassation later put it in a 2009 decision, lower judges cannot require an 
“unquestionable scientific proof” (“une preuve scientifique certaine”).55
Furthermore, the 2008 rulings did not follow the Conseil d’État’s solution. 
According to the latter, causation must be presumed if the disease appeared 
51. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Feb. 27, 2007, 06-
10063.
52. See, e.g., Cour d’appel [CA] [regional court of appeal] Paris, 2 June 2006, RCA 2006, comm. 
306, note Christophe Radé. 
53. In a work accident case, the second civil chamber of the Cour de cassation confirmed a lower 
court decision which had recognized causation between a vaccination and multiple sclerosis. Cour de 
cassation [Cass.] [supreme court for judicial matters] 2e civ., May 25, 2004, 02-30981, Bull civ. II, No. 
237 (ruling on Cour d’appel (CA) Metz, June 11, 2002, 99/02280).
54. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., May 22, 2008, 06-
10967, 05-20317, 06-18848, 06-14952, Bull. civ. I, No. 148-149.
55. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., June 25, 2009, 08-





      05/10/2016   13:13:34
37837-ckt_91-2 Sheet No. 64 Side B      05/10/2016   13:13:34
06 BORGHETTI-FINAL (DO NOT DELETE) 4/14/2016 7:31 PM
556 CHICAGO-KENT LAW REVIEW [Vol 91:2
in the three months following the vaccination and no other cause for the 
disease is identified. The Cour de cassation did not set such a rule, but only 
required lower courts to decide, on the facts of the case, if a presumption of 
causation may be retained.
The position adopted by the Cour de cassation in effect grants lower 
courts full freedom in assessing the existence of causation between a vac-
cination and a demyelinating disease. Acknowledging such causation has 
become a matter of presumption “on the facts,” over which the Cour de 
cassation exerts no control. As subsequent cases have shown, this inevita-
bly leads to diverging approaches by lower courts. Very similar circum-
stances can lead to different rulings on the issue of causation, depending on 
the lower judges’ conception of the etiology of demyelinating diseases.56 It 
seems as though scientific truth varies from one local jurisdiction to the 
other. Typically, the Paris appellate court seems to be very open to the epi-
demiologists’ argument, and usually decides that the facts of the case do 
not allow a presumption that the vaccination caused the demyelinating dis-
ease, whatever the delay between the former and the outbreak of the latter. 
Quite to the contrary, the Versailles appellate court (located only 20 km 
away!) readily accepts time proximity between the vaccination and the first 
symptoms of the disease as proof of causation, when no other factors ex-
plaining the disease can be found in the plaintiff or his family.57 For many 
French judges, the state of scientific uncertainty regarding the relationship 
between the hepatitis B vaccination and demyelinating disease is thus not 
an obstacle to legal causation being established between the two. This by-
passing of scientific uncertainty is worth investigating.
56. For cases in which lower judges considered causation as established on the facts of the case, 
see Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., July 9, 2009, 08-11073, Bull. 
civ. I, No. 176; Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., July 10, 2013, 12-
21314, Bull. civ. I, No. 157. For cases where lower judges have refused to acknowledge causation, see 
Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Sept. 24 2009, 08-16097; Cour de 
cassation [Cass.] [supreme court for judicial matters] 1e civ., Nov. 25 2010, 09-16556, 09-71013, Bull. 
civ. I, No. 245; Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Apr. 28, 2011, 10-
15289; Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Jan. 26, 2012, 10-28195; 
Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., June 28, 2012, 11-14287; Cour de 
cassation [Cass.] [supreme court for judicial matters] 1e civ., May 29, 2013, 12-20.903, Bull. civ. I, No. 
116.
      57. On this issue, see Jean-Sébastien Borghetti, Contentieux du vaccin contre l’hépatite B : en 
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II. THE BYPASSING OF SCIENTIFIC UNCERTAINTY
The solutions reached by French courts, and which have just been de-
scribed, are hardly satisfying. The position adopted by the Conseil d’État
lacks any explicit justification, whereas the Cour de cassation’s position 
results in considerable legal disorder and unpredictability. Part A examines 
how, more generally, the desire to grant compensation to plaintiffs, while 
pretending to abide with existing legal rules, leads judges to rely on pseu-
do-scientific reasoning. Part B suggests that clearer conceptual distinctions 
are needed, especially on the issue of causation, in order to reach better, or 
at least more convincing, solutions.
A. Pseudo-Scientific Reasoning
The majority of academia approved of those cases in which judges 
ruled that scientific uncertainty did not bar the establishment of causation 
between a hepatitis B vaccination and the outbreak of a demyelinating dis-
ease—at least in so far as those cases are favorable to plaintiffs.58 On a 
more technical ground, some authors try to justify those decisions by the 
simple idea that legal causation is not scientific causation.59 Even if this 
58. Of course, establishing causation is not always enough for a compensation claim to succeed. 
When the claim is grounded on the compulsory vaccinations compensation scheme, causation between 
the vaccination and the disease is indeed sufficient. Most claims, however, are based on product liabil-
ity and directed at the producer. In these claims, the plaintiff must also prove the defect in the product,
and this may be even harder than proving causation. In its latest rulings, however, the Cour de cassation
tried to go over this obstacle, just as it went over the causation obstacle. On two occasions, the Court 
quashed lower court decisions, which had recognized the existence of causation between a vaccination 
and multiple sclerosis on the facts of the case, but had nevertheless rejected the plaintiff’s claim on the 
ground that the risk/benefit ratio of the vaccine was positive, and the vaccine therefore not defective.
Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., July 10, 2013, 12-21314, Bull. 
civ. I, No. 157; Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., Sept. 26, 2012,
11-17738, Bull. civ. I, No. 187. In both cases, the Cour de cassation ruled that the lower courts could 
not rely only on the risk/benefit ratio to rule out defectiveness and that they should have considered if 
the elements that were used to presume causation could also justify a presumption that the vaccine dos-
es used were defective. By doing so, the Cour de cassation did not say that hepatitis B vaccines are de-
fective, but it allowed lower courts to reach this conclusion on a case-by-case basis. The approach is 
therefore exactly the same as the one taken on causation in 2008, and the result will also be the same. 
This means that the hepatitis B vaccine will most likely be regarded as defective by some French lower 
courts, but not by others. This, obviously, is neither convincing nor satisfying.
59. See Philippe Brun, Raffinements ou faux-fuyants ? Pour sortir de l’ambiguïté dans le conten-
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distinction is to be accepted, however, this justification is hardly convinc-
ing, as judges tend to put forward arguments, which they present as scien-
tific, in order to justify the solutions they reach. French courts therefore do 
not make a clear distinction between scientific causation and legal causa-
tion. Quite to the contrary—they very often mix up the two.
A 2009 case decided by the Cour de cassation offers a good illustra-
tion of this. The case involved all the elements that are commonly put for-
ward to justify the recognition of a causal relationship between a vaccina-
tion and the outbreak of a demyelinating disease, be it before 
administrative or civil courts.60 Mrs. X, a young woman, developed the 
first symptoms of multiple sclerosis a few weeks after she received a hepa-
titis B vaccine. The first instance court of Lyons rejected her product liabil-
ity claim against the producer of the vaccine on the ground that “mere 
chronology” cannot suffice to establish a link between a vaccination and 
the disease (“la seule chronologie ne peut suffire à imputer la survenue de 
la sclérose en plaques à la vaccination”).61 The appellate court of Lyons 
later reversed this judgment, and ruled that the connection between the 
vaccination and the disease could be presumed on the facts of the case.62
This new decision was then challenged before the Cour de cassation, and 
was confirmed. The justification given by the Cour de cassation for the re-
jection of the challenge was as follows: “having noted, first of all, that if 
scientific studies produced by [the vaccine manufacturer] do not establish a 
significant increase of the relative risk of multiple sclerosis or demye-
lination after a vaccination against hepatitis B, yet they do not exclude a 
possible link between this vaccination and the outbreak of a multiple-
sclerosis-like demyelination; having also noted that the first symptoms of 
multiple sclerosis appeared less than two months after the last injection of 
the product; [and having noted] that neither Mrs X nor any member of her 
family had previous neurological history, and, thus, that no other cause 
could explain this disease, whose link with the vaccination was regarded as 
evident by Mrs X’s practitioner; the appellate court, which was sovereign 
in deciding that these facts amounted to serious, precise, and consistent 
60. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., July 9, 2009, 08-11073,
Bull. civ. I, No. 176. 
61. Tribunal de grande instance [TGI] [ordinary court of original jurisdiction] Lyons, Mar. 27, 
2006, 05/10454.
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presumptions,63 could come to the conclusion that there was a causal con-
nection between Mrs X’s vaccination and her injury.”64
It can be deduced from this statement by the Cour de cassation that, as 
long as science does not exclude the existence of a causal connection, the 
finding that there is such a connection is possible. Legal causation is thus 
not totally independent from scientific causation, or at least cannot contra-
dict it openly.65 With this requirement that there be no contradiction with 
formal scientific findings, the elements which have been retained by lower 
judges to regard causation as established, and which the Cour de cassation
has accepted, are the following: 1) time proximity between the last injec-
tion of the vaccine and the first symptoms of the disease; 2) absence of 
neurological history and, more generally, of any other cause that could ex-
plain the outbreak of the disease; and 3) the intimate belief of the plaintiff’s 
practitioner. These elements must be considered in turn.
First of all, the practitioner’s conclusion that his patient’s disease had 
been caused by the vaccination, is certainly worth considering. Yet, it is ra-
ther surprising that it is given the same weight as the above-mentioned sci-
entific studies, especially as nothing indicates that this practitioner had spe-
cial expertise in the field of multiple sclerosis or neurological diseases. It is 
therefore not very surprising that this element is not frequently relied on.
Quite to the contrary, the second element (that there was no other 
cause than the vaccination that could explain the outbreak of the disease) is 
very often put forward. It may be formulated in slightly different ways, and 
courts sometimes underline, like the Conseil d’État66 or the appellate court 
in Mrs. X’s case, that there was no history of the disease in the plaintiff or 
his family. It is true that, generally speaking, eliminating alternative causes 
63. This is a reference to article 1353 of the Code civil. See supra Part I(A)(2)(b).
64. Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., July 9, 2009, 08-11073,
Bull. civ. I, No. 176. “Ayant relevé, d’abord, que si les études scientifiques versées aux débats par [le 
fabricant du vaccin] n’ont pas permis de mettre en évidence une augmentation statistiquement significa-
tive du risque relatif de sclérose en plaques ou de démyélinisation après une vaccination contre 
l’hépatite B, elles n’excluent pas, pour autant, un lien possible entre cette vaccination et la survenance 
d’une démyélinisation de type sclérose en plaques ; qu’ayant, ensuite, relevé que les premières manifes-
tations de la sclérose en plaques avaient eu lieu moins de deux mois après la dernière injection du 
produit ; que ni Mme X. . . ni aucun membre de sa famille n’avaient souffert d’antécédents neu-
rologiques, et que dès lors aucune autre cause ne pouvait expliquer cette maladie, dont le lien avec la 
vaccination relevait de l’évidence selon le médecin traitant de Mme X. . ., la cour d’appel, qui a sou-
verainement estimé que ces faits constituaient des présomptions graves, précises et concordantes, a pu 
en déduire un lien causal entre la vaccination de Mme X. . ., et le préjudice”. Id. (the French transla-
tion).
65. See infra Part II(B).
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can prove the causal link between two events.67 For such reasoning to be 
valid, however, it is necessary that all possible causes of the event whose 
origin is under investigation be identified. The problem with multiple scle-
rosis is that its etiology is not yet fully known.68 In this context, how is it 
possible for judges to assert that, in any given case, there could be no other 
cause than the vaccination to account for the outbreak of the disease? In 
particular, the fact that there was no history of the disease in the plaintiff’s 
family can be regarded as convincing only if it is assumed that multiple 
sclerosis normally develops out of internal or genetic factors; but the courts 
give no justification for this assumption.
The major element put forward to establish causation is the proximity 
in time between the vaccination and the onset of the first symptoms of the 
disease. It seems as though for many judges, as well as for many in aca-
demia, this proximity is the ultimate proof of causation. The importance of 
this element is especially clear in the decisions of the Conseil d’État.69 Un-
doubtedly, such a time coincidence between the vaccination and the ap-
pearance of the first symptoms of a demyelinating disease is disturbing, 
and it is not surprising if some plaintiffs are convinced that this is more 
than a coincidence. One can regard such a coincidence as proof of causa-
tion, however, only if one implicitly assumes that the vaccination can cause 
a demyelinating disease and that the disease will then occur in a very short 
time after the vaccination. Without such an underlying theory, the mere co-
incidence of two facts does not bear any significance. Viewing the coinci-
dence of time as proof of causation therefore amounts to holding true the 
theory that should have been demonstrated in the first place. A French au-
thor has put it very clearly:
“Does one not see that this proximity in time is significant only if one 
holds as true precisely what calls for a demonstration? Indeed, absent the 
presupposition, in one way or the other, that the injection of the vaccine 
and the disease are linked to one another, the near concomitance of these 
two events would not have any particular meaning, and would hardly be 
worth mentioning. This is made all the clearer by the fact that, to this 
day, the time needed for the said disease to develop its effects is not 
known. In such a context of ignorance, the proximity in time between the 
two events does not hint unambiguously to anything in particular. As a 
matter of fact, should it appear in the future that multiple sclerosis re-
mains latent in the body for several years before the onset of the first 
67. For examples in French law, see G. VINEY ET AL., LES CONDITIONS DE LA RESPONSABILITÉ ¶
382 (4th ed. 2013). 
68. See supra Part I(A)(1).
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symptoms, the near concomitance of the two events would appear as the 
sign of the absence of causation between them!” 70
Scientists have of course investigated the disturbing fact that the first 
symptoms of a demyelinating disease sometimes appear shortly after a 
hepatitis B vaccination. Most of their studies conclude, however, that such 
a coincidence cannot be regarded as significant from a statistical point of 
view. In other words, given the overall number of people who receive a 
vaccination against hepatitis B and the overall number of people who de-
velop a demyelinating disease, the number of cases in which such a disease 
appears shortly after a vaccination, appears to be in line with what statistics 
would predict in the absence of any causal relationship between the vac-
cination and the occurrence of a demyelinating disease. In fact, some stud-
ies even seem to suggest that, given the development pattern of demyelinat-
ing diseases, if the vaccination can cause a demyelinating disease, then the 
first symptoms of the disease should probably appear several years after the 
vaccination.71 If this were true, the time coincidence between the vaccina-
tion and the first symptoms of the disease would become proof that the 
former did not cause the latter.
As a result, the elements most commonly put forward to justify a pre-
sumption that the plaintiff’s demyelinating disease was caused by a vac-
cination against hepatitis B are not really convincing. Judges pretend not to 
be tied by science and do not want to consider the state of scientific uncer-
tainty resulting from existing epidemiological studies as an obstacle, but 
the arguments and reasoning they use to find causation are also of scientific 
nature—or at least pretend to be. When a court regards the concomitance in 
time to find that there is indeed causation, it relies implicitly on a pseudo-
scientific general rule, whereby the negative side effects of the vaccination, 
if any, must appear very quickly. By doing so, judges actually replace cau-
sation, as understood by scientists and epidemiologists, with their own 
brand of “scientific causation”. It is as though they implicitly concluded
70. G. Canselier, De l’explication causale en droit de la responsabilité civile délictuelle, 41 
REVUE TRIMESTRIELLE DE DROIT CIVIL 41, ¶ 20. (2010). “Ne voit-on pas que cette proximité tempo-
relle n’est significative que si l’on tient pour acquis précisément ce qui appelle démonstration ? En ef-
fet, si l’on ne présupposait pas, d’une manière ou d’une autre, que l’injection du vaccin et l’apparition 
de la maladie sont reliées l’une à l’autre, la quasi-concomitance de ces deux événements n’aurait pas 
de signification particulière et mériterait à peine d’être relevée. Ceci apparaît d’autant plus clairement 
que l’on ne connaît pas aujourd’hui le temps nécessaire pour que la maladie en question manifeste ses 
effets. Dans un tel contexte d’ignorance, la proximité temporelle des deux événements n’est l’indice 
univoque de rien. En effet, s’il devait apparaître à l’avenir que la sclérose reste latente dans 
l’organisme plusieurs années avant son déclenchement, la quasi-simultanéité des deux événements ap-
paraîtrait finalement comme le signe d’une absence de lien causal entre eux !” Id. (the French transla-
tion). 
71. C. Confavreux, Vaccination Contre L’hépatite B et Sclérose en Plaques, 34 LA PRESSE 
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that they know better than scientists: “Scientists may well tell us that time 
coincidence is no proof of causation, but we know that it is!” Presuming 
causation on the facts of the case, despite the state of scientific uncertainty, 
is thus not substituting legal causation for scientific causation, but rather 
substituting scientific causation as understood by (some) lawyers for scien-
tific causation as understood by scientists. This is hardly satisfying. A
change in the French courts’ position could more easily be made, however, 
if new concepts and distinctions were made available to judges in order for 
them to better address the questions with which they are faced.
B. Distinguishing Different Types of Causation
The traditional distinction between scientific and legal causation can-
not provide a solid justification for the solutions currently given by French 
courts in the field of hepatitis B vaccination litigation. Admittedly, scien-
tific causation and legal causation are distinct, but the fact that they should 
be distinguished does not mean that they are totally independent from one 
another, or that they can be at odds. Indeed, if it were to be scientifically 
proven that a vaccination against hepatitis B does not cause demyelinating 
diseases, it is quite likely that the Cour de cassation and the Conseil d’État
would change their position, since their rulings suggest that causation may 
be found in certain circumstances—despite the state of scientific uncertain-
ty—only because existing epidemiological studies do not formally exclude 
the existence of causation, even if they do not support it.
Putting forward the distinction between scientific causation and legal 
causation is just a way to bypass the obstacle of scientific uncertainty. It 
would be much better to face it openly. But this is made more difficult by 
the fact that French tort law lacks the conceptual tools needed to address 
and overcome this obstacle. The section of the French Code civil devoted to 
tort law only consists of five articles, three of them being either redundant 
or of very limited scope. The fundamental provision is article 1382,72
which states: “Every act whatever of man that causes damage to another, 
obliges him by whose fault it occurred to repair it.”73 The very general 
character of this principle has given French tort law distinctive flexibility. 
       72. This provision will remain unchanged but will be shifted to article 1240 when the reform of 
French contracts law (on which see supra note 26) comes into force on Oct. 1, 2016.
73. CODE CIVIL [C. CIV.] [CIVIL CODE] art. 1382. “Tout fait quelconque de l’homme, qui cause à 
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The courts, and especially the Cour de cassation, have made extensive use 
of this flexibility, with a view towards fostering compensation. According-
ly, they have always refused to give precise definitions of the key concepts 
contained in the articles of the Code civil. The result of this is that French 
tort law is structured around a limited number of ill-defined concepts, the 
three basic ones being fault, damage and causation.74 This, obviously, does 
not provide many tools to address the issue of scientific uncertainty in hep-
atitis B vaccination litigation. Causation is a pertinent concept in this con-
text, but French law does not have a clear definition of it. Besides, French 
law usually views causation as only the link between fault and damage; but 
this fails to capture the fact that tort cases can actually involve different 
types of causal relationships.75 It is suggested that at least two distinctions 
should be established in that respect.
First of all, the relationship existing between the use of the product 
and damage should be distinguished from the connection that may exist be-
tween the product’s defect and damage. Product liability regimes like the 
one established by the European Directive only mention the second con-
nection, which they call causation. For example, article 1 of the Directive 
provides that “the producer shall be liable for damage caused by a defect in 
his product.”76 Yet, although the relationship existing between the use of 
the product and damage is not mentioned, and thus receives no distinct 
name, it is an implicit prerequisite of liability.77 When French courts talk of 
causation in hepatitis B vaccination cases, and more generally in product 
liability cases involving pharmaceuticals, they usually have in mind the 
first relationship, i.e. the one between the use of the product and damage, 
and not the second one between defect and damage.
The second distinction that could and should be made is quite familiar 
to many American lawyers, and has an even closer connection to the issue 
of scientific uncertainty. It is the distinction between general causation and 
       74. Id. 
75. The distinction between cause in fact and cause in law, which many legal systems have 
adopted, though under different guises, is not officially recognized in French law.
76. Council Directive 85/374/EEC, art. 1, 1985 O.J. (L 210) (EU). This text has been implement-
ed at article 1386-1 of the Code civil: “Le producteur est responsable du dommage causé par un défaut 
de son produit, qu’il soit ou non lié par un contrat avec la victime.” CODE CIVIL [C. CIV.] [CIVIL CODE]
art. 1386-1 (“A producer is liable for the damage caused by a defect in his product, whether he was 
bound to the victim by a contract or not.”).
77. This has been acknowledged by the Cour de cassation in a couple of decisions. Cour de cas-
sation [Cass.] [supreme court for judicial matters] 1e civ., Feb. 27, 2007, 06-10063; Cour de cassation 
[Cass.] [supreme court for judicial matters] 1e civ., May 29, 2013, 12-20.903, Bull. civ. I, No. 116.
Some authors, however, are very critical of this solution, arguing that it creates a new hurdle on the path 
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specific (or individual) causation.78 General causation deals with the issue 
of whether a substance is capable of causing a particular injury or condition 
in the general population, whereas specific causation has to do with wheth-
er a substance caused a particular individual’s injury. This distinction may 
seem basic to some common lawyers who have some expertise in the field 
of toxic torts, but it is totally absent from French law.
French lawyers should adopt this distinction. An immediate benefit 
would be a better identification of the core difficulty in the hepatitis B vac-
cination cases. The problem in those cases is determining not only if the 
vaccine caused the plaintiff’s disease (specific causation), but also whether 
this product is generally capable of causing such a disease, independently 
from the case under discussion (general causation). In light of this distinc-
tion, the question, which French courts and lawyers have been grappling 
with for more than a decade, can be formulated very simply: should the 
proof of general causation be a prerequisite for the possibility, or even the 
admissibility, of the proof of specific causation?
American law generally seems to answer this question in the affirma-
tive. This is also substantially the position that the Cour de cassation
adopted in 2003,79 even if it did not use the concepts of general and specif-
ic causation. Today, however, both the Cour de cassation and the Conseil 
d’État implicitly accept that specific causation can be established even 
though general causation has not been proven. There seems to be a logical 
problem there. Admittedly, the prerequisite of general causation could be 
set aside if the plaintiff’s injury were attributable to some specific charac-
teristics of the vaccine doses he received, and not to the vaccine’s general 
characteristics. But the plaintiffs in the hepatitis B vaccine litigation cases
have never seemed to suggest this.80
Distinguishing general causation and specific causation thus more 
plainly exposes the contradiction in the position adopted by (some) French 
78. See, e.g., Baxter v. Healthcare Corp., 397 F.3d 878 (10th Cir. 2005); In re Hanford Nuclear 
Reservation Litig., 292 F.3d 1124, 1129 (9th Cir. 2002) (“‘Generic causation’ has typically been under-
stood to mean the capacity of a toxic agent, such as radiation, to cause the illnesses complained of by 
plaintiffs. If such capacity is established, ‘individual causation’ answers whether that toxic agent actual-
ly caused a particular plaintiff’s illness.”); In re Rezulin Prods. Liab. Litig., 369 F. Supp. 2d 398, 402 
(S.D. N.Y. 2005); Soldo v. Sandoz Pharms. Corp., 244 F. Supp. 2d 434, 524–25 (W.D. Pa. 2003); Bur-
ton v. R.J. Reynolds Tobacco Co., 181 F. Supp. 2d 1256, 1266–67 (D. Kan. 2002); see also
RESTATEMENT (THIRD) OF TORTS: PHYSICAL & EMOTIONAL HARM § 28 cmt. c (AM. LAW INST. 2010).
79. See supra Part I(B)(2).
80. On the other hand, the Cour de cassation has done so in two decisions, but in a rather uncon-
vincing way, which is essentially an implicit recognition that its current position is not convincing. See
Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., July 10, 2013, 12-21314, Bull. 
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courts. They pretend to apply tort law rules and to appraise causation on the 
basis of objective elements and scientific reasoning, but they actually resort 
to a biased logic, and use tort law as a smoke-screen to try and grant com-
pensation, whose real justification does not lie in the application of tort law 
rules, but in the desire to help plaintiffs attracting their compassion.
This actually illustrates two distinctive traits of French case law in the 
field of tort law. The first one is the tendency to take an instrumentalist ap-
proach to the law and to twist, or bend, tort law rules in order to foster 
compensation. This might seem surprising, especially in a legal system 
based on written provisions, where the judge’s role is traditionally under-
stood as being only to apply the law, and not to create it. In the field of 
torts, however, the lack of guidance offered by the Code civil, combined 
with the necessity to answer society’s changing needs, has created an inci-
tation for the courts to take a more proactive role. They started to do so at 
the end of the 19th century,81 and have progressively set themselves free 
from the legislature—at least in the fields the legislature has left untouched 
since 1804.82 More recently, French courts have tended to set themselves 
free from mere logic, especially on the issue of causation—and hepatitis B 
vaccination litigation offers a topical, but by no way unique, example of 
this trend.83 This of course raises many questions, the most notable one be-
ing: what, if any, is the limit on judges’ discretion?
The other distinctive trait of French case law in the field of torts is 
that, despite their having gained so much freedom and discretion, higher 
judges, and especially the Cour de cassation, still pretend to be following
the legalist model and applying the law, without creating it. As a result, 
they continue handing down decisions, which are very short, that contain 
very little motivation, and give no indication of the policy considerations 
underlying the positions or rules that are adopted. This is partly due to the 
technicalities of the procedure before the Cour de cassation, but the result 
of it is a striking paradox: The Cour de cassation is a major source of tort 
81. The seminal case is Teffaine, in which the Cour de cassation created a new strict liability re-
gime on the basis of a provision of the Civil code which was intended to serve as an introduction, and 
not to state a rule. Cour de cassation [Cass.] [supreme court for judicial matters] civ., June 18, 1896, S. 
Jur. 1897, 1, 17.
82. On several occasions, the French legislature adopted special liability rules applicable to spe-
cific types of accidents. The most famous piece of legislation in that respect is a 1985 statute on traffic 
accidents, which imposes extra strict liability on drivers. See S. Whittaker, The Law of Obligations, in
BELL ET AL., supra note 17, at 400–02. Courts are normally much more respectful of the provisions 
contained in those special statutes than they are of the traditional Code civil provisions.
83. For another striking example in a wrongful death case, see Cour de cassation [Cass.] [su-
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law, but its power is to a large extent unchecked, and it does not even have 
to give its reasoning when it creates the law.
In this context, it is not surprising that French courts, and especially 
the Cour de cassation, should not be fond of new concepts or conceptual 
distinctions. To define more precisely some basic notions, like causation, or 
to distinguish explicitly between different types of causation—like courts 
in other countries commonly do—would restrict the discretion and the 
freedom they have been enjoying for so long. If French judges were con-
strained by hard concepts and precise distinctions, they could not regard 
causation as established rather offhandedly, or on the basis of dubious rea-
soning, as they do now. And this is precisely why French law needs those 
definitions and distinctions! In the particular case of hepatitis B vaccination 
litigation, adopting the distinction between general causation and specific 
causation would make it more difficult for judges to hide behind pseudo-
scientific arguments or reasoning in order to (try and) grant compensation 
to plaintiffs, despite the prevailing state of scientific uncertainty. They 
would have to either change their position concerning the proof of causa-
tion, or make their policy choices explicit by openly acknowledging that 
they believe that some plaintiffs must be granted compensation, even 
though they cannot demonstrate causation. Whether judges should be al-
lowed to opt for the latter option is debatable, but French courts could like-
ly do it by changing the burden of proof of causation in hepatitis B vaccine 
cases.84 This, it is suggested, would not be a good solution, but if judges are 
to bend the law, let them at least do so frankly.
84. French courts have already done this in other types of litigation involving medical products, 
but never when there were doubts on general causation. See, e.g., Conseil d’État [CE] [Council of State] 
Jan. 15, 2001, 208958 and Cour de cassation [Cass.] [supreme court for judicial matters] 1e civ., May 9, 
2001, 99-18161, 99-18514, Bull civ, No. 130 on the issue of hepatitis contamination through blood 
transfusions.
